Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (3): 377-380    DOI: 10.12892/ejgo3733.2018
Original Research Previous articles | Next articles
The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China
K. Yao1, †, C. Bian1, †, L. Li1, Y. Wu1, X. Zhao1, *()
1 Department of Obstetrics and Gynecology, Affiliated West China Women's and Children's Hospital of Sichuan University, Chengdu, China
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
To evaluate the outcomes of neoadjuvant chemotherapy (NACT) for patients with advanced epithelial ovarian cancer (EOC), and to identify predictors of response to NACT by analyzing the characteristics of patients and guiding future therapy choices in China. Three to four courses of NACT followed by interval cytoreductive surgery (ICS) were utilized to treat advanced EOC patients. The median overall survival (OS) in NACT response group was significantly longer than that of the no response group. Patients with International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV were more likely to respond to NACT. Optimal cytoreductive surgery (OCS) was achieved in 80 (70.2%) patients among 114, and complete cytoreductive surgery (CCS) was achieved in 34 (29.8%) patients. The median OS of patients with no residual tumor was significantly longer than those with residual tumors of 0.1-1.0 cm. The median OS of the ten patients who did not receive surgery was notably worse than patients with residual tumor > 1.0 cm. CA125 sensitivity and specificity were 40.8% and 86.7%, respectively. Present studies provided evidences that NACT was a viable remedy for patients with advanced EOC in China.
Key words:  Epithelial ovarian cancer (EOC)      Neoadjuvant chemotherapy (NACT)      Interval cytoreductive surgery (ICS)     
Published:  10 June 2018     
*Corresponding Author(s):  X. ZHAO     E-mail:  zhaoxiasc@sina.com
About author:  † Contributed equally.

Cite this article: 

K. Yao, C. Bian, L. Li, Y. Wu, X. Zhao. The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China. European Journal of Gynaecological Oncology, 2018, 39(3): 377-380.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3733.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I3/377

[1] X. Li, J. Yang, X. Wang, X. Li, J. Liang, H. Xing. Role of TWIST2, E-cadherin and Vimentin in epithelial ovarian carcinogenesis and prognosis and their interaction in cancer progression[J]. European Journal of Gynaecological Oncology, 2016, 37(1): 100-108.
No Suggested Reading articles found!